Wells Fargo Upgrades Editas Medicine to Overweight from Equal-Weight
Fintel reports that on October 8, 2026, Wells Fargo upgraded their outlook for Editas Medicine (NASDAQGS:EDIT) (LSE:0IFK) from Equal-Weight to Overweight.
Editas Medicine, Inc., based in the United States, operates within the biotechnology sector and is notable for its pioneering efforts in gene editing technology. Specializing in the CRISPR/Cas9 and CRISPR/Cas12 systems, the company focuses on developing transformative gene-editing therapies to treat a diverse range of diseases with unmet medical needs. Key projects include a leading development program targeting Leber Congenital Amaurosis type 10 (LCA10), a severe genetic eye disorder, endeavoring to correct this mutation-driven ailment at the DNA level. Additionally, Editas Medicine sustains active research in exploring treatment options for other genetic conditions, including sickle cell disease and beta-thalassemia, signifying its strategic commitment to medical innovation and genetic disease treatment.
Prior to this rating action, the stock closed at $2.75 on October 7, 2026. This is also the latest close price as of October 7, 2026. Looking at recent market performance, the stock experienced a price change of +7.00% over one week, relative to a baseline close of $2.57 on September 30, 2026. Over a one-month period, the price change was -14.86% from a baseline close of $3.23 on September 4, 2026.
Separately, the consensus target price for the stock was recorded at a mean of $6.12 and a median of $5.10 as of October 2, 2026, representing an implied change of +122.55%. This consensus target mean represents a revision of -2.33% from the prior consensus target mean of $6.27 recorded on September 15, 2026.
In its latest earnings report on August 5, 2026, Editas Medicine reported an actual EPS of -0.15, compared to an estimated EPS of -0.2753. The company reported actual revenue of $11,890,000.00, which exceeded the estimated revenue of $2,856,102.00.
For the current recommendation period of September 1, 2026, the aggregate analyst recommendations consisted of 5 strong buy, 7 buy, 4 hold, 2 sell, and 0 strong sell ratings, totaling 18 recommendations. This breakdown represents 66.7% positive, 22.2% hold, and 11.1% negative recommendations. This is unchanged from the prior recommendation period of August 1, 2026, which also had 4 strong buy, 8 buy, 4 hold, 2 sell, and 0 strong sell ratings, totaling 18 recommendations, with 66.7% positive, 22.2% hold, and 11.1% negative recommendations.
In other analyst activities, Guggenheim upgraded the stock from Neutral to Buy on September 23, 2026.
Recent analyst actions
| Date | Analyst | Prior | Latest recommendation | Action |
|---|---|---|---|---|
| October 8, 2026 | Wells Fargo | Equal-Weight | Overweight | upgrade |
| September 23, 2026 | Guggenheim | Neutral | Buy | upgrade |
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.